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Abstract
Histone hypoacetylation is associated with dopaminergic
neurodegeneration in Parkinson’s disease (PD), because of
an imbalance in the activities of the enzymes responsible for
histone (de)acetylation. Correction of this imbalance, with
histone deacetylase (HDAC) inhibiting agents, could be
neuroprotective. We therefore hypothesize that nicotinamide,
being a selective inhibitor of HDAC class III as well as having
modulatory effects on mitochondrial energy metabolism, would
be neuroprotective in the lactacystin rat model of PD, which
recapitulates the formation of neurotoxic accumulation of
altered proteins within the substantia nigra to cause progres-
sive dopaminergic cell death. Rats received nicotinamide for
28 days, starting 7 days after unilateral injection of the
irreversible proteasome inhibitor, lactacystin, into the substan-
tia nigra. Longitudinal motor behavioural testing and structural
magnetic resonance imaging were used to track changes in
this model of PD, and assessment of nigrostriatal integrity,
histone acetylation and brain gene expression changes post-
mortem used to quantify nicotinamide-induced neuroprotec-
tion. Counterintuitively, nicotinamide dose-dependently
exacerbated neurodegeneration of dopaminergic neurons,
behavioural deﬁcits and structural brain changes in the lacta-
cystin-lesioned rat. Nicotinamide treatment induced histone
hyperacetylation and over-expression of numerous neu-
rotrophic and anti-apoptotic factors in the brain, yet failed to
result in neuroprotection, rather exacerbated dopaminergic
pathology. These ﬁndings highlight the importance of inhibitor
speciﬁcity within HDAC isoforms for therapeutic efﬁcacy in PD,
demonstrating the contrasting effects of HDAC class III inhibi-
tion upon cell survival in this animal model of the disease.
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Parkinson’s disease (PD) is the most common movement
disorder, presenting clinically as a triad of symptoms,
notably tremor, muscle rigidity and bradykinesia, as a result
of neurodegeneration of the dopamine producing cells of the
Substantia Nigra pars compacta (SNpc) in the brain (Dexter
and Jenner 2013). The hallmarks of these degenerating
neurons in PD are intracytoplasmic inclusions, Lewy bodies,
containing altered proteins such as the synaptic protein, a-
synuclein (aSyn), which are thought to attribute to the
nigrostriatal neurodegeneration observed in the disease
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(Dexter and Jenner 2013). It has been previously demon-
strated that nuclear aSyn ‘masks’ the histone proteins around
which DNA is coiled, preventing their acetylation and as
such the resulting histone hypoacetylation is thought to
contribute to neurodegeneration in PD (Kontopoulos et al.
2006). In addition, it has been observed that in neurodegen-
erative states, there is a critical imbalance between the
activities of the two enzymes which control histone acety-
lation: histone acetyltransferases and histone deacetylases
(HDACs), in favour of histone deacetylation, exacerbating
the hypoacetylation of histone proteins (Rouaux et al. 2003).
It has been hypothesized then that perhaps HDAC inhibitors
(HDACIs) may act therapeutically by rectifying the misbal-
ance between histone (de)acetylation, reducing histone
hypoacetylation-mediated neurodegeneration in PD (Har-
rison and Dexter 2013).
To date, four main classes of HDACs have been
described: classes I (HDACs 1, 2, 3 and 8), IIa (HDACs
4, 5, 7 and 9), IIb (HDACs 6 and 10), III (Sirtuins 1–7) and
IV (HDAC 11) (Xu et al. 2007), with numerous isoform
selective and isoform non-selective HDACIs now available.
Appropriately, inhibitors of a number of these classes and
sub-classes of HDACs have shown to produce a neuropro-
tective effect in cell and animal models of PD (for reviews
see Harrison and Dexter 2013; Sharma and Taliyan 2015).
For example we have demonstrated previously that delayed
systemic treatment with valproate, an inhibitor of HDAC
classes I and IIa, causes neuroprotection and neurorestora-
tion of dopaminergic neurons within the SNpc and ventral
tegmental area in the lactacystin rat model of PD (Harrison
et al. 2015, 2016). HDAC Class III, the sirtuins, however,
are enzymatically and structurally disparate from the
remaining three classes of ‘classical’ HDACs. And as such
inhibitors of this class are relatively under investigated
because of the unavailability of selective sirtuin inhibitors.
Recent advances in the ﬁeld, however, have highlighted
sirtuin1 and 2 as potential targets in PD (Garske et al. 2007;
Outeiro et al. 2007; Donmez and Outeiro 2013; Chen et al.
2015; Harrison et al. 2018), and as such recent years have
witnessed the development of novel inhibitors of these
HDACs for the study of their therapeutic beneﬁt in
neurodegeneration (Cui et al. 2014; Tatum et al. 2014; Di
Fruscia et al. 2015; Sundriyal et al. 2017). At present,
however, research is hampered by the lack of pharmacoki-
netic study of these novel agents, more speciﬁcally whether
or not they are able to penetrate the blood–brain barrier
efﬁciently enough to produce selective HDAC inhibition in
the brain.
Nicotinamide (niacinamide or nicotinic amide), is an
amide converted, in vivo, from its dietary precursor niacin
(nicotinic acid, a.k.a. vitamin B3). This B vitamin is found in
various food sources, most abundantly in beef, chicken, pork,
ﬁsh, peanuts, mushrooms, green beans, sunﬂower seeds and
avocado. Pharmacologically, nicotinamide does not have the
same adverse effects as high doses of niacin (cutaneous
ﬂushing and itching) which occur incidental to niacin’s
conversion. Rather, it displays a linear relationship between
maximum recorded plasma concentrations and the dose in
grams in man, exhibits maximal plasma levels around
30 min after dosing, and higher doses maintain high plasma
levels for up to 4 h (Dragovic et al. 1995). Being a precursor
for nicotinamide adenine dinucleotide (NAD+), nicotinamide
is known to non-selectively inhibit HDAC class III through
competition binding to the sirtuin HDAC’s NAD+ binding
site (Avalos et al. 2005), and given its relatively low
molecular weight (122.12 g/mol) is known to easily cross
the blood–brain barrier (Spector 1987). It has therefore
gained increased interest as a neuroprotective agent in
neurodegenerative conditions. Furthermore, nicotinamide is
known to have modulatory effects on cellular energy
metabolism, which is known to become defective in
dopaminergic neurons in PD, and hence even greater focus
has been placed upon the potential use of this agent in PD
(Beal 2003).
In the absence of brain penetrant highly selective/potent
sirtuin inhibitors, it is vitally important to assess whether
non-selective sirtuin inhibitors like nictotinamide are neuro-
protective, particularly since it may also correct the cellular
energy imbalance observed in PD. Importantly, this study
therefore aims for the ﬁrst time to investigate the neuropro-
tective effect of nicotinamide in an animal model which
recapitulates the formation of neurotoxic accumulation of
altered proteins within the SNpc to cause progressive
dopaminergic cell death: the lactacystin rat model, and hence
mimics closely the pathological process of PD. Furthermore,
a delayed start study design will be used to model the clinical
scenario in which a neuroprotective drug would be admin-
istered to an already degenerating system, hence adding
novelty since this will replicate more accurately the drug
effect in the early stages of PD. In addition, molecular and
cellular analyses of study samples will attempt to elucidate
the neuroprotective mechanism of nicotinamide’s HDAC
inhibition in this model.
Methods
Experimental animals
Animal procedures were previously approved by Imperial College
London’s Animal Welfare and Ethical Review Board and carried out
according to the UK’s Home Ofﬁce Animals (Scientiﬁc Procedures)
Act of 1986 (PPL No.: 70/7398). This study was not pre-registered.
A total of 33 adult male Sprague–Dawley rats (250  10 g; Charles
River, Margate, Kent, UK, RRID:MGI:5651135) were used in this
study, transported to Imperial College London’s animal holding
facility 2 weeks prior to use, where they were group housed (2–3
per cage) in temperature (21  1°C), and humidity (55  10%)
controlled individually ventilated cages, on a 12-h (7 am to 7 pm)
light–dark cycle. Ad libitum drinking water and rat chow were
available for the duration of the study, which was supplement
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post-surgery with wet rat diet for 7 days. ARRIVE guidelines
(Kilkenny et al. 2010) were adhered to in reporting of experimen-
tal ﬁndings.
Animal treatment groups
Assessments of longitudinal changes in brain structure by Magnetic
Resonance Imaging (MRI) and motor behavioural performance
were made in four groups of animals (Fig. 1, n = 6–7, no sample
size differences between the start and end of experiments). These
measurements were taken at baseline, prior to lesion of the SNpc
with lactacystin, and again at weeks 1, 3 and 5, post-lesioning. To
conﬁrm appropriate lactacystin lesioning of the SNpc, any animal
which failed to perform ipsilateral rotations in the amphetamine-
induced rotation test (see below) was excluded from further study.
No animals were excluded on this basis. Animals received daily
injections (i.p.) for 28 days (at the same time each day, 10–11 am)
with either saline (Baxter, Newbury, Berkshire, UK, #FKE1324) or
doses of nicotinamide (Sigma, Dorset, UK, #N3376) previously
shown to have neuroprotective effects in animal models of PD
(Anderson et al. 2006, 2008) (250 mg/kg or 500 mg/kg in saline),
starting at day 7 post lactacystin lesioning. This time point was
chosen for initiation of treatment having previously been shown to
exhibit signiﬁcant dopaminergic pathology following lactacystin
lesioning (Harrison et al. 2015). After ﬁnal behavioural and MRI
measurements, animals were culled, and brains removed for
analysis. Treatment and assessment of the control group (Lacta
()Saline()) of animals was performed ﬁrst followed by
experimental groups (Lacta(+)NTA(), Lacta(+)NTA(+) and
Lacta(+)NTA(++)). No randomization was performed.
In addition to the four treatment groups detailed above (Fig. 1), a
separate cohort of male Sprague–Dawley rats (250  10 g, n = 7)
were injected daily for 28 days with the higher dose of nicotinamide
used in the study (500 mg/kg, i.p.), to determine the effects of
nicotinamide alone on the cellular and molecular readouts reported
in the four study treatment groups. After the ﬁnal i.p. injection on
day 28, these animals were culled, and brains removed for analysis.
See Figure S1.
Stereotaxic lesioning of the SNpc with lactacystin
Rats were rendered unilaterally Parkinsonian, by stereotaxic injec-
tion of the irreversible proteasome inhibitor, lactacystin (Enzo Life
Sciences, Exeter, UK, #BML-PI104) into the left SNpc, as
previously published (Harrison et al. 2015). Animal were anaes-
thetized with isoﬂurane (Teva, Castleford, UK, #32035519), and
positioned in the horizontal skull position into a stereotaxic frame
(Kopf Instruments, Tujunga, CA, USA, #900). Isoﬂurane anaesthe-
sia was chosen for stereotaxic lesioning of the SNpc as previous
studies from our group have shown that this regime results in the
greatest level of dopaminergic degeneration on SNpc lesioned,
compared to other commonly used small animal anaesthetics (Datla
et al. 2006). Vidine antiseptic scrub (EcoLab, Cheshire, UK.
#3030440) was applied to the scalp before a midline incision was
made to expose the skull. Bregma was identiﬁed (Paxinos and
Watson 2009), and above the location of the SNpc, a small burr hole
was made. With use of a 10 lL Hamilton syringe (Sigma, #701N),
Fig. 1 Animal treatment groups and study design. *All daily i.p.
injections given as 2 mL/kg: saline injections given as 2 mL/kg empty
saline; 500 mg/kg nicotinamide injections given as 2 mL/kg of 250 mg/
mL solution of nicotinamide in saline; 250 mg/kg nicotinamide injec-
tions given as 2 mL/kg of 125 mg/mL solution of nicotinamide in saline.
#Only groups Lacta(+)NTA(), Lacta(+)NTA(+) and Lacta(+)NTA(++)
intranigrally injected with lactacystin. Control group remained surgically
na€ıve. ǂOnly groups lesioned with lactacystin were tested using the
amphetamine-induced rotation test at these time points. N numbers
determined empirically based on previous work with the lactacystin rat
model and magnitude of neuroprotection expected. VCT, vertical
cylinder test; AIR, amphetamine-induced rotations; MRI, magnetic
resonance imaging.
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10 lg of lactacystin (2.5 lg/lL in sterile saline, 4 lL in total) was
injected (1 lL/min) at the location of the left SNpc: anterio-
posterior, 5.2 mm, medio-lateral, +2.5 mm and ventral to dura,
7.6 mm (Paxinos and Watson 2009). The needle was left in place
for 3 min prior to being retracted and suturing of the scalp
incision. Animals were then left to recover in a heated recovery
chamber before being returned to their home cages. In order to
minimize animal suffering following stereotaxic surgery a
number of measures were taken. Firstly, local anaesthesia, in
the form of subcutaneous bupivacaine (Mercury Pharma, London,
UK, #02848/0198), was administered at the scalp 3 min prior to
making the initial incision. In addition, in order to alleviate post-
operative pain, analgesia, in the form of buprenorphine (Veter-
gesic; Alstoe Animal Health, York, UK, #117299), was admin-
istered intramuscularly prior to recovery. Lastly, post-surgery
ﬂuid replacement (Glucosaline, 5 mL of 0.18% NaCl, 4%
Glucose, (Baxter, #FE1253) given i.p. prior to surgery) was
given in order to prevent dehydration during recovery. In the days
following surgery, sutures were checked for signs of infection,
and antibiotic ointment applied (Isaderm; Dechra, Northwich,
UK, #570831) daily.
Behavioural testing
The unilateral lesioning of the nigrostriatal tract in the animals
induces an asymmetry in motor function between the left and right-
hand sides of the body, and the extent of the asymmetry is
proportional to the extent of the lesion. The vertical cylinder test and
amphetamine-induced rotation test were utilized to quantify motor
asymmetry, longitudinally.
Vertical cylinder test
The vertical cylinder test (Schallert et al. 2000) was used to make
longitudinal assessment of forelimb asymmetry in study animals, as
previously published (Harrison et al. 2015). Brieﬂy, animals were
placed into a custom made clear Perspex cylinder (30 cm in height,
20 cm in diameter) and a video camera used to record rearing
behaviour for 3 min, or 10 complete rears, whichever came ﬁrst. In
a blinded fashion, ofﬂine frame-by-frame analysis was used to
examine forelimb movements, calculating the % contralateral
forelimb use (N) as:
Amphetamine-induced rotation test
The amphetamine-induced rotation test (Ungerstedt and Arbuthnott
1970) was used to make longitudinal assessment of rotational
asymmetry, as previously published (Harrison et al. 2015). Brieﬂy,
rats were treated with amphetamine (5 mg/kg (at 5 mg/mL in sterile
saline) D-amphetamine sulphate (Sigma, #A5880), i.p.) and left to
acclimatize for 30 min in a clear circular test arena (36 cm in height,
40 cm in diameter, Circling Bowl; Harvard Apparatus, Cambridge,
MA, USA, #CMA8309031). Behaviour was then recorded with a
video camera for a further 30 min, prior to animals being returned to
their home cages. In a blinded fashion, ofﬂine quantiﬁcation of the
number of ipsiversive (anticlockwise) and contraversive (clockwise)
rotation, in bins of 5 min, was performed, calculating the net
ipsiversive rotations (N) as:
N ¼ ðipsiversive rotationsÞ  ðcontraversive rotationsÞ
Further to this, the area under the curve (AUC) produced by
plotting number of N vs. time, was also calculated as a gross
measure of test performance.
Magnetic resonance imaging
Longitudinal acquisition of in vivo magnetic resonance (MR) images
of the rat brain was performed in order to quantify and track
progression of neuropathology in the lactacystin rat model of PD, as
previously published (Harrison et al. 2015). Images were acquired on
a 4.7 Tesla DirectDrive horizontal small bore MRI scanner (Varian,
Palo Alto, CA, USA), with radio frequency transmitted and received
using a 72 mm quadrature birdcage head coil (M2M Imaging,
Richmond Heights, OH, USA). Animals were anaesthetized in an
anaesthetic chamber with isoﬂurane in O2, prior to being transferred
into a polytetraﬂuroethylane MRI compatible head holder, and
anaesthesia maintained by delivery of isoﬂurane in O2 via a nose
cone. A respiratory balloon (SA Instruments, Stony Brooks, NY, USA,
#1030) placed under the animal’s thorax, was used to monitor depth of
anaesthesia, while a rectal probe and warm air blower (SA Instruments,
#1030) were used to monitor and maintain core temperature. A multi-
echo, multi-slice spin-echo pulse sequence (MEMS) was used to
acquire T2-weighted images: FOV = 35 mm 9 35 mm; matrix =
192 9 192; TR = 5155.2 ms; TE = 10, 20, 30, 40, 50, 60, 70, 80, 90,
100 ms; 4 averages, scan duration 1 h 5 min 59 s. 50 coronal image
slices (in plane resolution of 256 9 256 lm), with a thickness of
500 lm, were acquired, covering the entirety of the animal’s brain.
Post-acquisition, the ten echo time for each acquired image were
summed [‘Z Project’ function in ImageJ (v1.4, National Institutes of
Health, Bethesda, MD, USA)] resulting in 50 contiguous T2-weighted
images. Following image acquisition, animalswere removed to a heated
recovery chamber in order to allow recovery from anaesthesia, before
being returned to their home cages.
MR image analysis
Manual segmentation analysis and also unbiased, automated,
tensor-based morphometry of acquire T2-weighted images were
used to examine changes in neuropathology over time, and to
quantify the effects of nicotinamide treatment on lactacystin-
lesioned animals.
Manual segmentation analysis
With reference to a rat brain atlas (Paxinos and Watson 2009),
delineation of structures (lateral ventricles, corpus striatum, hip-
pocampus and midbrain) was performed manually by a single rater
blind to animal treatment (ImageJ), as previously published
(Harrison et al. 2015). Multiplication of the delineated area (lm2)
N ¼ ðcontralateral forelimb placementsþ
1
2 placements of both forelimbs simultaneouslyÞ  100Þ
ðipsilateral forelimb placementsþ contralateral forelimb placementsþ placements of both forelimbs simultaneously)
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by the slice thickness (500 lm) gave the volume (lm3), which was
then converted to % change from baseline in order to ascertain
changes in volumes over time.
Tensor-based morphometry
We applied tensor-based morphometry analysis to images acquired
from all treatment groups at week 5 post-lesioning, to search for
relative differences in brain volume. For this, structural analysis of MR
images brains were oriented to a standard space and intensity non-
uniformity correction applied using the N4ITK algorithm (Tustison
et al. 2010). Brains were then masked semi-automatically, by
manually masking a single rat brain using ITK-Snap (Yushkevich
et al. 2006), prior to other brain images being registered to this
masked image using the open-source NiftyReg package (12 degrees of
freedom afﬁne registration, available from: http://sourceforge.net/
projects/niftyreg, (Modat et al. 2014)). The mask was resampled to
each image’s space (with nearest neighbour interpolation) using the
inverted resulting afﬁne transformation matrices. Intensities between
images were standardized within their respective masks, using the
method described by Nyul et al. (Nyul et al. 2000). All images were
then group-wise registered into a single target ‘atlas’ space (Cleary
et al. 2011). Group registration attempts to align equivalent anatomical
regions between all images, by applying a deformation ﬁeld. For initial
alignment, a single target brain was chosen at random and all other
images rigidly registered to it. This was followed by nine iterations of
afﬁne registration and 15 iterations of non-rigid registration, using a
symmetric implementation of free-form deformation (Modat et al.
2012). After each iteration, images were resampled into the middle
space and their intensity average generated and used as the following
iteration’s target. Following registration, the Jacobian determinant was
calculated at each voxel in the resulting deformation ﬁelds. The
determinant describes the voxel-wise expansion or contraction of each
image to meet the ﬁnal average. These were log-transformed and
smoothed (Gaussian kernel, FWHM 0.2 mm). Finally, two-tailed t-
tests were performed at each voxel between all images, using contrasts
with the General Linear Model to compare groups’ local volume
differences. False Discovery Rate correction was applied (q = 0.1) to
control for multiple tests (Benjamini and Hochberg 1995). The
resulting statistical maps are shown in Fig. 4.
Tissue collection and preparation
After study completion, animals were culled through inhalation of
CO2, decapitated and the brain quickly removed out of the skull.
The brains were the cut coronally, at the level of the infundibular
stem, producing forebrain (containing the striatum) and hindbrain
(containing the SNpc) tissue blocks. The frontal block was snap
frozen on dry ice and stored, prior to extraction of mRNA and
protein, at 80°C. The hind block was drop ﬁxed for 72 h in 4%
paraformaldehyde (Sigma, #P6148) in phosphate-buffered saline
(PBS) (pH 7.4), after which it was croyoprotected by submerging in
30% sucrose (Sigma, S9378) in PBS, until the block was observed
to have sunk. This tissue was then snap frozen, in pre-chilled (on dry
ice) isopentane (Sigma, #M32631) and stored at 80°C prior to
sectioning for immunohistochemical staining.
Immunohistochemistry
Hind brain tissue was sectioned and immunohistochemically stained
as previously published by our group (Harrison et al. 2015). Brieﬂy,
tissue containing the SNpc was ﬁrstly cryosectioned coronally
(30 lm thickness) using a cryostat (Bright Instruments, Huntingdon,
UK), onto SuperFrost Plus slides (VWR international, Lutterworth,
Leicestershire, UK, #631-0108), and stored at 80°C prior to
analysis. To assess the extent of nigrostriatal dopaminergic cell loss
on the lesioned and unlesioned side of the brain, immunohisto-
chemical staining of dopaminergic neurons in the SNpc was utilized.
For this, tyrosine hydroxide (TH), an enzyme involved in
monoamine synthesis in these neurons, was used as a marker, and
cresyl violet used as a counter-stain in order to label the Nissl body
of neurons, as previously published (Harrison et al. 2015). Avidin-
Biotin Complex/peroxidase immunohistochemistry was used.
Brieﬂy, activity of endogenous peroxidase was ﬁrstly blocked by
incubating sections in 0.3% H2O2 (Sigma, #H1009) in methanol
(Sigma, #322415) for 45 min. Sections were then put through a
descending series of alcohols in order to rehydrate them, before
washing in PBS containing 0.1% TritonX-100 (Sigma, #X100)
(PBS-T). Sections were then blocked for 1 h at 21C in 20% normal
goat serum (VectorLabs, Peterborough, UK, #S-1000) in PBS-T,
and then incubated in primary TH antibody (1 : 1000 in PBS-T,
Rabbit Polyclonal Anti-Tyrosine Hydroxylase, #AB152; Millipore
Corporation, Bedford, MA, USA, RRID:AB_390204) for 24 h at
21C. Secondary antibody was applied to sections (1 : 200 in PBS-
T, Biotinylated Goat Anti-Rabbit Secondary Antibody; VectorLabs,
#BA-1000) for 1 h at 21C, after washing in PBS-T. After
secondary incubation, tissue was washed again in PBS-T before
being incubated in Avidin-Biotin Complex (Vectastain Elite ABC
Kit; VectorLabs, #PK-6100) for 1 h at 21C. Sections were then
washed in tris-buffered saline (TBS) (pH 8.4) before being
immunopositive staining was visualized with 3, 30-diaminobenzi-
dine (VectorLabs, #SK-4100). Sections were then ﬁnally washed
with H2O and counter-stained with cresyl violet (0.1% in dH2O)
(Sigma, #C5042) prior to dehydration (ascending series of alcohols
and xylene) and mounting in Distyrene, dibutyl Phthalate, Xylene
(DPX).
Stereological cell quantification
Stereological (optical fractionator method (West et al. 1991))
quantiﬁcation of the number of TH positive (TH+) and Nissl
positive (Nissl+) cells were made in the entire SNpc, with the
experimenter blinded to treatment group, as previously published
(Harrison et al. 2015). For this, a Nikon Eclipse E8 – microscope
(Nikon Instruments, Amsterdam, Netherlands), JVC (UK) 3CCD
camera, and stereology software system (ImagePro; MediaCyber-
netics, Rockville, MD, USA) was used. Firstly, an area of interest
(AOI) was draw digitally on the section, based on previously
published boundaries of the SNpc (Carman et al. 1991). Counting
frames (140 9 160 lm), were then placed on this AOI using the
uniform random sampling method. TH+ and Nissl+ cells within
these frames were then counted using ‘acceptance’ (north and west)
and ‘forbidden’ (south and east) lines where cells were observed to
penetrate these lines, to avoid edge effects. Estimates of total cell
numbers (N) within the SNpc were calculated using the below
equation:
N ¼ nð1=ssfÞð1=asfÞð1=hsfÞ
Where the section sampling fraction (ssf) is given as 1/6, owing to
every 6th section of the SNpc being assessed. The area sampling
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fraction (asf) is given by the total counting frame area relative to the
AOI area. And the height sampling fraction (hsf) is given by
measuring the optical dissector height (average of three random
points) height assessed using a Heidenhain microcator (Heidenhain,
Traunreut, Germany, #MT60)) relative to the sectioned thickness
(30 lm).
Protein and mRNA extraction and quantification
A tissue homogenizer (Ultra-Turrax T18; IKA, Oxford, Germany)
was used to homogenize 30 mg of frontal brain tissue in
QIAzol Lysis Reagent (Qiagen, Manchester, UK, #79306).
The RNeasy Plus Universal Mini Kit (Qiagen, #73404) was
then used for extraction of protein and mRNA, as per the
manufacturer’s instructions. Extracted protein quantity was mea-
sured by Bradford Assay (Sigma, #B6916), determining colour
change with a 96-well plate reader (VersaMax Microplate Reader;
Molecular Devices, Palo Alto, CA, USA, #VERSAMAX) at A595.
Extracted RNA purity and quantity was measured using a
NanoDrop ND-1000 spectrophotometer (Labtech, Heathﬁeld, East
Sussex, UK) [mean A260/280 ratio = 1.99 (range 1.97–2.01)].
Extracts were stored at 20°C (protein) and 80°C (RNA) until
analysis (see below).
Protein quantiﬁcation: western blot analysis
A common acetylation site of H3 (lysine residue 9) (AcH3-Lys9),
was quantiﬁed in protein extracts from the frontal brain as a measure
of histone acetylation in the brain as previously published (Harrison
et al. 2015). Brieﬂy, 10 lg of extracted protein sample was
denatured (95°C for 15 min) in Laemmli sample buffer (Sigma,
#S3401) prior to being loaded onto a hand-cast 1 mm thick 15%
Tris-Glycine gel and electrophoretically separated (65 mA for
40 min). Proteins were then semi-dry transferred (20 V for
45 min) onto polyvinylidene diﬂuoride membrane (0.45 lm pore
size) soaked in methanol, and equilibrated in TBS containing 0.2%
Tween-20 (TBS-T). Membrane non-speciﬁc antibody binding was
blocked (5% non-fat milk in TBS-T, 1 h at 21C) prior to incubation
of membranes with primary antibodies for both AcH3-Lys9 (rabbit
anti-AcH3-Lys9, 1 : 10 000; Sigma, #H9286, RRID:AB_477076)
and b-actin as a loading control (mouse anti-b-actin, 1 : 20 000;
Abcam, Cambridge, UK, #Ab6276, RRID:AB_2223210) for 1 h a
21C. After washing, membranes were incubated with horseradish
peroxidase-conjugated secondary antibodies (either Goat anti-
Rabbit, 1 : 10 000, and Horse anti-Mouse, 1 : 10 000, for AcH3-
Lys9 or b-actin, respectively, both VectorLabs, #PI-1000 and #PI-
2000) for 1 h at 21C, prior to positive signal being visualized and
developed onto photographic ﬁlm using chemiluminescence (Clarity
Western ECL Substrate; Bio-Rad, Watford, Hertfordshire, UK,
#1705060). Protein bands were quantiﬁed densitometrically (Ima-
geJ, v1.4).
mRNA quantiﬁcation: quantitative real-time polymerase chain
reaction
In addition to extraction of protein for quantiﬁcation of histone
acetylation, mRNA was also extracted from excised brain samples
for quantiﬁcation of the expression levels of SNCA, brain-derived
neurotrophic factor (BDNF), glial-derived neurotrophic factor
(GDNF), HSPA1A, GSN, BCL2 and BAD, as previously published
by our group (Harrison et al. 2015), as changes in the expression
levels of the proteins corresponding to these genes have been
previously to be associated with HDACI treatment (Monti et al.
2009). Brieﬂy, cDNA was synthesized from extracted mRNA, by
reverse transcription of 500 ng total RNA using the QuantiTect re-
verse transcription kit (Qiagen, #205311) with integrated removal of
genomic DNA contamination. This was then quantiﬁed using real-
time reverse transcriptase quantitative polymerase chain reaction
(RT-qPCR) on an Mx3000PTMreal-time PCR system with MxPro
software (v4.10; Stratagene, La Jolla, CA, USA). Duplex reactions
were set up in triplicate, containing 10 lL of 29 Brilliant II QPCR
master mix (Agilent Technologies UK Ltd, Stockport, Cheshire,
UK, #600806), 1 lL of 109 PrimeTimeTMqPCR assay for the novel
reference gene X-prolyl aminopeptidase (aminopeptidase P) 1
(XPNPEP1) (Durrenberger et al. 2012), 1 lL of 109 PrimeTi-
meTMqPCR assay for the gene of interest, 7 lL RNase free H20 and
1 lL of sample cDNA. For full probe and primer sequences of
PrimeTimeTM qPCR assays (Integrated DNA Technology, Coral-
ville, IA, USA), see table 1. Reactions were activated at 95°C for
10 min, followed by running of 60 cycles of a three step
thermocycler program (95°C for 30 s, 55°C for 30 s and 72°C for
30 s), acquiring ﬂuorescence data at the annealing step. Normalized
relative expression was computed from CT values using the 2
DDCT
method (Livak and Schmittgen 2001), normalizing to the appropri-
ate control group.
Statistical analysis
All data are presented as either mean  standard error of mean
between animals in line graphs, or as box-plots; with the middle line
representing the median, the box representing the 25th to 75th
percentiles and whiskers presenting the minimum and maximum
values, with a + representing the mean in each box. No calculation
was performed to predetermine the sample size, nor was any test for
outliers. Prior to between-group statistical analysis, data normality
was conﬁrmed using the Kolmogorov–Smirnov test. Vertical
cylinder test, amphetamine-induced rotation test and MRI manual
segmentation datasets were analysed using two-way (repeated
measures) analysis of variance (ANOVA) tests with Bonferroni post-
tests. In addition, a paired t-test was used to compare the baseline
and week 1 forelimb use of lactacystin-lesioned animals in vertical
cylinder test data. Differences between stereological cell counts in
the ipsilateral and contralateral hemispheres of animal brains were
tested using paired t-tests, with a one-way ANOVA with Bonferroni
post-tests used to compare percentages of cell loss from counts. A
two-way ANOVA with Bonferroni post-tests was used to compare
qRT-PCR data, and lastly a one-way ANOVA with Bonferroni post-
tests was used to compare western blot data. All statistical analyses
was performed using GraphPad Prism (v5.0 for Windows;
GraphPad Software Inc., San Diego, CA, USA).
Results
Nicotinamide exacerbates behavioural motor deficits caused
by lactacystin
Vertical cylinder test
At baseline there was equal use of both the left and right
forelimb in all animals (Fig. 2a). However, 1 week after
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surgery there was a signiﬁcant asymmetry in forelimb paw
usage as evidenced by a reduction in the contralateral
forelimb use of lactacystin-lesioned animals compared with
non-lesioned animals (paired t-test, p < 0.01). Contralateral
forelimb use of the lactacystin-lesioned, saline-treated
animals continued to decline with time over the 5 week
study period. However, in lactacystin-lesioned animals
subsequently treated with the low dose of nicotinamide
starting at day 7 post-lesioning, a slight alleviation of this
motor behavioural deﬁcit was observed at weeks 3 and 5:
contralateral forelimb use in this animal treatment group
after 28 days of nicotinamide (250 mg/kg) treatment
recovering by 5.87  2.39% (p > 0.05 compared to non-
lesioned animals at week 5). This markedly contrasted to
the animals treated with the high dose of nicotinamide,
where the contralateral forelimb use continued to decline
with time but at a faster rate than that observed in the
saline-treated lactacystin-lesioned animals; resulting in a
further 8.92  8.08% reduction in contralateral forelimb
use after 28 days of nicotinamide (500 mg/kg) treatment
(p < 0.001 compared to non-lesioned animals, and
p < 0.05 compared to low-dose nicotinamide-treated ani-
mals, at week 5).
Amphetamine-induced rotation test
Ipsilateral rotations following an amphetamine challenge
were observed at 1 week in all lactacystin-lesioned animals
(Fig. 2b). Saline-treated lactacystin-lesioned animals per-
formed increasing numbers of rotations over the further two
time points examined (Fig. 2c, AUC produced by plotting
number of rotations vs. time; week 1, 612.08  121.59;
week 3, 1039.33  247.75; week 5, 1641.00  477.50).
Treatment of animals with a low dose of nicotinamide
(250 mg/kg) did not markedly attenuate the number of
amphetamine-induced rotations observed in later time
points of the study. However, animals subsequently treated
with a high dose of nicotinamide exhibited a marked
exacerbation in the number of amphetamine-induced rota-
tions, observed at both weeks 3 and 5 (AUC produced by
plotting number of rotations vs. time, p < 0.05 and p < 0.01
compared to saline-treated and low-dose nicotinamide-treated
lactacystin-lesioned animals, respectively, at both 3 and
5 weeks post-lesion).
MRI reveals dose-dependent exacerbation of lactacystin-
induced volumetric changes by nicotinamide
Manual segmentation analysis
In surgically na€ıve animals, the volume of the lateral
ventricles increases comparably in both hemispheres over
the 5 week study (Fig. 3b). However, lactacystin-lesioned
animals subsequently treated with saline, exhibited a greater
increase in ventricular enlargement over the 5 weeks of
study, a change which was more pronounced in the lesioned
hemisphere. Nicotinamide treatment of animals resulted in a
dose-dependent exacerbation of ipsilateral ventricular
enlargement over the study period, resulting in animals
treated with the high dose (500 mg/kg) of nicotinamide
exhibiting signiﬁcantly larger ipsilateral ventricles than both
surgically na€ıve, and lactacystin-lesioned saline-treated ani-
mals by week 5 (Fig. 3b, p < 0.001 and p < 0.05 respec-
tively). Unsurprisingly, given the location of the SNpc in the
midbrain, and the injection of lactacystin into this brain
region to produce this animal model of PD, the midbrain was
the area observed to be most markedly affected in MR
images. One week after lesioning surgery, prior to com-
mencement of saline/nicotinamide treatment, the ipsilateral
midbrain volume of all lactacystin-lesioned animal groups
was signiﬁcantly lower than the volume of the surgically
na€ıve group (Fig. 3c, lactacystin-lesioned saline, 250 mg/kg
and 500 mg/kg nicotinamide-treated animals,
7.07  3.05%, 5.20  3.14% and 8.94  3.11% decrease
from baseline, respectively, vs. 10.88  4.73% increase
from baseline in the surgically na€ıve group, p < 0.05 in all
comparisons). The midbrain volume of the group of animals
lesioned with lactacystin and subsequently treated with
saline, continued to decline over the further two imaging time
points (week 3, 10.90  6.54% decrease from baseline;
week 5, 16.77  5.94% decrease from baseline, p < 0.01
and p < 0.001 compared to surgically na€ıve animals at week
3 and 5 respectively). The midbrain volume of both
lactacystin-lesioned nicotinamide-treated animal groups
(250 mg/kg and 500 mg/kg) also continued to decline over
the subsequent two imaging time points. However, this
decline in midbrain volume was far greater in both of these
groups compared to saline-treated lactacystin-lesioned ani-
mals (Fig. 3c, week 3, saline-treated animals,
10.90  6.54% decrease from baseline, compared to low-
and high-dose nicotinamide-treated animals, 25.81  0.99%
and 21.40  3.04% decrease from baseline respectively;
week 5, saline-treated animals, 16.77  5.94% decrease
from baseline, compared to low- and high-dose nicoti-
namide-treated animals, 26.23  1.99% and 28.56  3.42%
decrease from baseline respectively). Identical albeit more
subtle changes were similarly observed in the contralateral
hemisphere of the midbrain (Fig. 3c). Similarly, identical
albeit more subtle changes in volume decreases over time to
those observed in the midbrain were seen in both the corpus
striatum and hippocampus (Fig. 3d and e).
Tensor-based morphometry
Several distinct anatomical patterns were observed across
treatment groups (all data shown are corrected for multiple
comparison over voxels using the False Discovery Rate with
q < 0.1). When comparing the surgically na€ıve group of
animals to saline-treated lactacystin-lesioned animals, a
number of clusters of signiﬁcant voxels were observed
(Fig. 4ai and bi). Notably, as would be expected, shrinkage
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was observed in the Substantia Nigra, both in the pars
compacta and pars reticulata, accompanied by a cluster of
expanding voxels in the neighbouring ventricle. Primarily
this reﬂected an increase in cerebrospinal ﬂuid signal
accompanying deformation of the ventral midbrain. A small
cluster of contracting voxels was also observed in the
superior colliculus, and on the midline, contraction was also
observed in pineal recess and more ventrally, in the
interpeduncular nucleus. From the horizontal level of the
SNpc (Fig. 4bi), signiﬁcant contraction can also be observed
rostral and caudal to the site of lactacystin lesioning: in the
optic tract, and in the peduncular pontine and pontine
reticular nuclei. These data are consistent with prior obser-
vations in this model (Vernon et al. 2011; Harrison et al.
2015).
When comparing the surgically na€ıve group of animals to
low-dose (250 mg/kg) nicotinamide-treated lactacystin-
lesioned animals, a similar, yet enhanced pattern of contrac-
tion was observed compared to the drug na€ıve group
comparison (Fig. 4aii and bii). The contractions observed
in the midline when comparing surgically na€ıve to lacta-
cystin-lesioned saline-treated animals were absent. Yet a
greater number of signiﬁcantly contracted voxels were
observed in the superior colliculus, and also the SN, which
again was accompanied by enlargement of the neighbouring
ventricle. Similar to the non-drug-treated comparison, this
contraction in the SN was also observed to be extended
caudally into the pontine nuclei, yet to a greater degree.
In animals lesioned with lactacystin and subsequently
treated with the high dose (500 mg/kg) of nicotinamide, an
even greater extent of contraction was observed compared to
the surgically na€ıve treatment group (Fig. 4aiii and biii).
Firstly, a greater number of signiﬁcantly contracted voxels
were observed in the superior colliculus, extending laterally
into the pretectal nucleus and the optic tract. Similarly, a
larger cluster of signiﬁcantly contracted voxels was observed
in the SN, which again, from the horizontal orientation was
observed to extent into the pontine nuclei.
Nicotinamide treatment causes dose-dependent
exacerbation of dopaminergic neurodegeneration in the
SNpc of lactacystin-lesioned animals
Post-study, animals were culled and hind brain tissue
collected for immunohistochemical staining and stereolog-
ical quantiﬁcation of dopaminergic neurons (TH+ and
Nissl+) in the SNpc (Figs 5 and 6). No neuronal loss
between hemispheres was observed in non-lesioned animals
(Fig. 6a, non-lesioned animals, left hemisphere,
Table 1 Probe and primer sequences of PrimeTimeTM qPCR assays used
Gene Protein Sequence
XPNPEP1 XPNPEP1 Probe 50-/5HEX/CCATCATTC/ZEN/ACTACGCGCCGATCC/3IABkFQ/-30
Primer 1 50-GTTCCATCCTTGTACTGAGCA-30
Primer 2 50-TTCCCAACGATTTCCAGCA-30
SNCA a-Synuclein Probe 50/56-FAM/CTTCTCAGC/ZEN/CACTGTTGTCACTCCA/3IABkFQ/-30
Primer 1 50-CCCTCCAACATTTGTCACTTG-30
Primer 2 50-GCGTCCTCTATAGGTTCCA-30
BDNF BDNF Probe 50-/56-FAM/CAGCAAAGC/ZEN/CACAATGTTCCACCA/3IABkFQ/-30
Primer 1 50-GCAACCGAAGTCTGAAATAACCA-30
Primer 2 50-GACACATTACCTTCCAGCATCT-30
GDNF GDNF Probe 50-/56-FAM/CGCTGACCA/ZEN/GTGACTCCAATATGCC/3IABkFQ/-30
Primer 1 50-CAGTCTTTTGATGGTGGCTTG-30
Primer 2 50-GCCGAAGACCACTCCCT-30
HSPA1A HSP70 Probe 50-/56-FAM/CCGTGTTGT/ZEN/GGACAGTTGGTTGTG/3IABkFQ/-30
Primer 1 50-TGAGTGGAATGGACAGGAAAG-30
Primer 2 50-CATAATCAGAACTGTGCGAGTCT-30
GSN Gelsolin Probe 50-/56-FAM/CGCCAGGAA/ZEN/CCTCTTCGATCACAA/3IABkFQ/-30
Primer 1 50-CATCAGTAGCCAGGTCTTCC-30
Primer 2 50-GGCTTAAGGACAAGAAGATGGA-30
BCL2 BCL2 Probe 50-/56-FAM/CAGGATAAC/ZEN/GGAGGCTGGGATGC/3IABkFQ/-30
Primer 1 50-CCAGGAGAAATCAAACAGAGGT-30
Primer 2 50-GATGACTGAGTACCTGAACCG-30
BAD BAD Probe 50-/56-FAM/CCATAGTCC/ZEN/CAGCCCTCCATG/3IABkFQ/-30
Primer 1 50-CATCCCTTCATCTTCCTCAGTC-30
Primer 2 50-GACAGGCAGCCAATAACAGT-30
All PrimeTimeTM qPCR assays were obtained from Integrated DNA Technology (Coralville, IA, USA) and contained 2.5 nM of probe, 5 nM of primer
1 and 5 nM of primer 2. A, adenine; C, cytosine; G, guanine; T, thymine; HEXTM, Hexachloroﬂuorescein; IABkFQ, Iowa Black FQ.
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11724  729, right hemisphere, 11652  493, p > 0.05).
Animals lesioned with lactacystin and subsequently treated
with saline, however, exhibited a marked interhemispheric
loss of TH+ neurons, 53.81  13.26%. This loss was dose-
dependently exacerbated with nicotinamide treatment
(Fig. 6c and d, 81.41  3.35% and 85.87  4.63% inter-
hemsipheric loss in low (250 mg/kg) and high (500 mg/kg)
dose nicotinamide-treated animals respectively). All
changes observed in SNpc TH+ cell number were repro-
duced in the numbers of Nissl+ cells, indicative of TH+
neuronal cell death rather than loss of the TH enzyme
expression in dying neurons. Additionally, upon closer
examination of the degenerating SNpc in nicotinamide-
treated cohorts, TH+ neurons in animals treated with the
low dose of nicotinamide appear to retain their deﬁned TH+
neuronal cell body structure, yet in rats treated with the
high dose of nicotinamide, this structure appears lost: more
sparse, diffuse and dendritic TH staining is observed
(Fig. 5di’), indicative of the decline in dopaminergic
neuronal health in this treatment group.
Nicotinamide reverses lactacystin-induced reduction in
histone acetylation resulting in histone hyperacetylation in
the brain
Upon removal of brain tissue at the end of the study, the
frontal brain was snap frozen for subsequent quantiﬁcation of
histone acetylation through quantiﬁcation of AcH3-Lys9
using Western blot analysis (Fig. 7). A marked reduction in
AcH3-Lys9 was observed in both hemispheres of lactacystin-
lesioned animals treated with saline compared to non-
lesioned animals treated with saline, however, this change
was non-signiﬁcant. This lactacystin-induced effect of
Fig. 2 High doses of nicotinamide
exacerbate behavioural motor deﬁcits
caused by lactacystin lesioning of the
Substantia Nigra pars compacta. (a)
Vertical cylinder test outcomes show that
once animals begin treatment with
nicotinamide at week 1 (designated by
arrow and grey shading) the lactacystin-
induced reduction in percentage
contralateral forelimb use is slightly
alleviated upon treatment with a low dose
(250 mg/kg) of nicotinamide, however,
exacerbated upon treatment with a high
dose (500 mg/kg) of nicotinamide,
compared to saline-treated control animals.
(b and c) Amphetamine-induced rotation
test outcomes show that animals treated
with the low dose of nicotinamide (250 mg/
kg) perform slightly fewer rotations over
time, whereas animals treated with the high
dose of nicotinamide (500 mg/kg) exhibit far
greater rotational behaviour as a result of
drug treatment. Statistical signiﬁcance
denoted with either asterisks: (*p < 0.05,
**p < 0.01) or letters where p < 0.05 for
each comparison: aSigniﬁcantly different
from group Lacta()NTA(); bSigniﬁcantly
different from group Lacta(+)NTA();
cSigniﬁcantly different from group Lacta(+)
NTA(+). Data are presented as
mean  SEM, or as box-plots, with the
middle line representing the median, the
box representing the 25th to 75th
percentiles and whiskers presenting the
minimum and maximum values, with a +
representing the mean in each box. n = 6–7
animals per group.
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histone hypoacetylation, however, was reversed upon treat-
ment with nicotinamide, not only back to the levels observed
in non-lesioned animals, but more than two-fold greater,
resulting in signiﬁcant histone hyperacetylation in nicoti-
namide-treated animals’ brains (p < 0.01 in all compar-
isons).
Nicotinamide dose-dependently up-regulates expression of
neuroprotective proteins
In lactacystin-lesioned animals treated with saline, there was
a marked decrease in the expression of a number of
neurotrophic and neuroprotective factors in the brain, such
as aSyn, brain-derived neurotrophic factor, GDNF, gelsolin
and Bcl-2 (Fig. 8). These decreases, however, were not
signiﬁcant. Upon treatment of lactacystin-lesioned animals
with nicotinamide, however, a dose-dependent attenuation of
a number of these reductions were observed: high dose
(500 mg/kg) nicotinamide-treated animals displaying signif-
icantly greater expression levels of aSyn, Hsp70, gelsolin
and Bcl-2. These increased expression levels, however, were
far greater in animals treated with the higher dose of
nicotinamide, disproportionate to the dose of nicotinamide
animals were treated with.
Discussion
Nicotinamide dose-dependently exacerbated degeneration of
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Fig. 3 Manual segmentation analysis of MR images reveals exacer-
bation of lactacystin-induced volumetric changes upon treatment with
nicotinamide. (a) Representative examples of the manual segmentation
of (i) lateral ventricles, (ii) corpus striatum, (iii) midbrain and (iv)
hippocampus. Administration of nicotinamide (designated by arrow and
grey shading) exacerbates volumetric changes observed in the (b)
lateral ventricles, the (c) midbrain, the (d) corpus striatum and the (e)
hippocampus, as a result of lactacystin lesioning, as ascertained
through manual segmentation analysis of rat brain MR images.
Statistical signiﬁcance denoted with letters where p < 0.05 for each
comparison: a, signiﬁcantly different from group Lacta()NTA();
bSigniﬁcantly different from group Lacta(+)NTA() Data are presented
as mean  SEM. n = 6–7 animals per group.
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of PD. This is evident from exacerbation of deﬁcits in motor
behaviour, brain volume changes assessed using longitudinal
MRI, and ex vivo assessment of dopaminergic neuron cell
numbers in the SNpc. Molecular analyses indicated that
nicotinamide not only reversed lactacystin-induced histone
hypoacetylation in the brain but also induced histone
hyperacetylation in nicotinamide-treated animal brains. This
translated to dose-dependent up-regulations of numerous
neuroprotective protein genes; however, these did not result
in neuroprotection in this model of neurodegenerative
disease, rather exacerbated neurodegeneration. Careful inter-
pretation of these results and comparison to previously
published similar datasets will help to understand how and
why, nicotinamide, a HDACI which has been previously
shown to act neuroprotectively in models of PD, exacerbates
neurodegeneration in the lactacystin rat model of the disease.
Nicotinamide has received increased interest in neurode-
generative disease research in recent years because of it being
previously shown to reduce infarct size and resultant
neurological deﬁcits in models of stroke (Ayoub et al.
1999; Mokudai et al. 2000; Liu et al. 2009), improve
cognition in Alzheimer’s disease transgenic mice (Green
et al. 2008), and up-regulate neurotrophic factors in models
of Huntington’s disease leading to improved motor scores
(Hathorn et al. 2011). Additionally, in contrast to the results
observed here, nicotinamide has also previously been shown
to act neuroprotectively in animal models of PD (Anderson
et al. 2006, 2008). In previous published mouse studies
using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
a mitochondrial complex 1 inhibitor used to cause neurode-
generation selectively within the SNpc by way of energy
starvation and free radical production, nicotinamide demon-
strated a neuroprotective phenotype. Peripheral administra-
tion of nicotinamide before MPTP injection, resulted in dose-
dependent neuroprotection in the ‘acute’ MPTP (four
injections in 1 day at 2 h intervals) but not in the ‘sub-
acute’ model (two injections per day at 4 h intervals for
5 days) of PD. In this ‘sub-acute’ model, subtle neuropro-
tection was observed, but nowhere near that shown in the
‘acute’ dosing strategy (Anderson et al. 2006, 2008). These
ﬁndings are in direct contrast to those presented here. The
key difference between these previous studies and that
presented here is the toxin used to induce dopaminergic
degeneration within the SNpc. Nicotinamide is a precursor of
(ai) (aii) (aiii)
(bi) (bii) (biii)
Fig. 4 Tensor-based morphometry validates ﬁndings from manual
segmentation analyses of rat brain MR images. Regions of signiﬁcant
volume difference for each treatment group compared with Lacta()
NTA() at week 5 are shown, overlaid onto representative slices of the
group average image. Positive differences (blue) indicate local volume
increases in group compared with Lacta()NTA() and negative
differences (red) indicate local volume decreases in group compared
with Lacta()NTA(). Two orientations are shown at the (a) coronal
and (b) horizontal levels of the Substantia Nigra pars compacta.
Results shown are signiﬁcant after correction for multiple comparisons
across voxels using the False Discovery Rate with q = 0.1. n = 6–7
animals per group. C, contralateral; I, ipsilateral.
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NAD+ and is therefore, in addition to its effects as a HDACI,
thought to be involved with brain energy metabolism and
preservation of mitochondrial functionality: an increasingly
attractive prospect for neuroprotection in PD (Beal 2003).
MPTP works through inhibition of mitochondrial complex 1
to cause mitochondrial dysfunction and energy starvation in
dopaminergic neurons. It may well be likely then that
nicotinamide, in the MPTP model, would directly counteract
the effects of this mitochondrial toxin because of its effects
on bioenergetics, hence translating to a neuroprotective
phenotype observed in the studies by Anderson et al. (2006,
2008). Energy starvation and free radical production,
however, are by no means the only mechanisms through
which dopaminergic neurodegeneration is thought to take
place in PD, rather a complex interaction of several
pathways, with aSyn protein deposition at the centre. To
provide a more complete understanding of the potential of
nicotinamide as a neuroprotective agent in PD then, its
effects on other mechanistically distinct animal models of the
disorder must be investigated.
More akin to the neuropathological picture of degeneration
in clinical PD, SNpc toxicity in the rat brain was induced in
this study through protein deposition, thought to be the












Fig. 5 Neurodegeneration in the Substantia Nigra pars compacta
(SNpc) of lactacystin-lesioned animals. Representative examples of the
TH and Nissl stained ipsilateral (ai–di) and contralateral (aii–dii) SNpc of
rats in each of the four treatment groups. Insets (ai’–di’), allow closer
morphological examination of the degenerating SNpc in each treatment
group. Scale bar equal to 500 lm.
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acetylation in PD. This was achieved through SNpc injection
of the irreversible proteasome system inhibitor, lactacystin,
shown previously to induce aSyn protein deposition in
residing dopaminergic neurons (McNaught et al. 2002;
Fornai et al. 2003; Miwa et al. 2005; Niu et al. 2009;
Vernon et al. 2010, 2011; Xie et al. 2010; Lorenc-Koci
et al. 2011; Du et al. 2014; Bentea et al. 2015; Pienaar et al.
2015). Rather than recapitulating the neuroprotective pheno-
type observed in the MPTP mouse model, nicotinamide
appeared to act in the opposing direction in this animal
model; exacerbating the effects of lactacystin-induced
nigrostriatal degeneration in the rat brain. When given in
isolation to healthy control rats, the high dose of
nicotinamide used in this study (500 mg/kg) for the same
time period (28 days) had no marked effect on nigrostriatal
integrity (see Figure S1). It induced subtle increases in
histone acetylation, and equally subtle changes in gene
expression (see Figure S1). When given after lactacystin
lesioning of the SNpc, however, we observed that nicoti-
namide-induced exacerbation of SNpc degeneration, histone
hyperacetylation and dramatic increases in gene expression.
It has been demonstrated previously in vitro, that other
HDACIs possess the ability to suppress the activity of the
ubiquitin–proteasome system and expression of its subunits
(Mitsiades et al. 2004). It may well be the case that in this
study the toxic effects of nicotinamide after lactacystin
Fig. 6 Nicotinamide treatment causes exacerbation of dopaminergic
neurons in the Substantia Nigra pars compacta (SNpc) in lactacystin-
lesioned animals. Stereologically estimated (a) TH+ and (b) Nissl+
neuron numbers in the SNpc of rats suggest that nicotinamide
exacerbates dopaminergic neurodegeneration in the lactacystin-
lesioned rat brain. This is exempliﬁed by the percentage interhemi-
spheric loss of TH+ (c) and Nissl+ (d) neurons calculated between
hemispheres of the SNpc. Statistical signiﬁcance indicated with
asterisks: **p < 0.01, ***p < 0.001. Data are presented as box-plots,
with the middle line representing the median, the box representing the
25th to 75th percentiles and whiskers presenting the minimum and
maximum values, with a + representing the mean in each box. n = 6–7
animals per group. C, contralateral; I, ipsilateral.
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lesioning are because of a synergistic inhibitory effect on
proteasome activity, providing a potential explanation of the
detrimental effects of the drug observed here. That being
said, drug/toxin interactions can largely be avoided with the
use of a delayed start treatment strategy, unlike the study
design used by Anderson et al., in their characterization of
the effects of nicotinamide in the MPTP model, in which
drug administration was commenced prior to toxin admin-
istration. In this study, however, drug treatment was
commenced 7 days after lactacystin lesioning, meaning that
the therapeutic was applied to an already degenerating
nigrostriatal system, mimicking more closely the clinical
scenario. It may well also be possible then, that by this time,
any neuroprotective potential of nicotinamide is outweighed
by the extent of further proteasomal inhibition, as a result of
lactacystin-induced protein deposition within dopaminergic
neurons; nicotinamide then acting to synergistically exacer-
bate toxicity via further activity suppression and reducing the
expression of ubiquitin proteasome system subunits (Mitsi-
ades et al. 2004).
Acetylation of histone lysine residues cause neutralization of
their charge, and reduced electrostatic interaction between the
phosphate group onDNA and the histone tail itself. Relaxation
of chromatin structure then results, as a function of the
disrupted histone and DNA inter- and intra-nucleosomal
interactions, allowing transcription factors to access DNA. In
our previous work, we showed that alleviation of histone
hypoacetylation in the lactacystin rat model, to near healthy
levels with the use of the class I and IIa HDACI valproate,
resulted in neuroprotection (Harrison et al. 2015). Here,
however, nicotinamide treatment, rather than lessening the
degree of histone hypoacetylation, completely reversed the
acetylation status in the brain, resulting in extensive histone
hyperacetylation in nicotinamide-treated animals. Such a
scenario has previously been observed to be neurotoxic in
dopaminergic neurons (Song et al. 2010). Consistent with
histone acetylation though, large dose-dependent up-regula-
tions of neuroprotective and neurotrophic geneswere observed
in the brains of nicotinamide-treated rats. In contrast to our
previous ﬁndings with valproate, however, in which drug-
induced up-regulation of neurotrophic factors (namely BDNF
and GDNF) translated to neuroprotection in the lactacystin rat
model of PD (Harrison et al. 2015, 2016), exacerbation of
pathology rather than protection is observed in this study. It is
important to note, however, that the level of histone acetylation
observed here upon treatment with nicotinamide was far
greater than that observed previously with valproate treatment
of the same animal model. It is therefore likely that extensive
histone hyperacetylation-induced chromatin relaxation, like
that observed here with nicotinamide, would not only induce
up-regulations of neuroprotective and neurotrophic genes,
such as those studied here, but also an array of other genes,
many of which possibly pro-death or pro-inﬂammatory in
nature. For example previous studies from the cancerﬁeld have
shown that histone hyperacetylation induced by HDACIs
induced a pro-apoptotic response in various cell types (Jeong
et al. 2011; Bolden et al. 2013; Fujiki et al. 2013). Addition-
ally, extensive microglial activation has been previously
observed in this animal model of PD (Ahn and Jeon 2006;
Pienaar et al. 2015), and there is evidence to suggest that
HDAC activation may indeed potentiate such activation by
increasing the expression of pro-inﬂammatory mediators
(Suuronen et al. 2003). Furthermore, it is important to
remember that the proﬁle of gene regulation and expression
quantiﬁed here is in the frontal brain of the lactacystin-lesioned
brain, and hence the proﬁle of gene expression changes in
degenerating dopaminergic neurons of the SNpc themselves,
may present a quite different picture. Further work should
hence aim to provide a more thorough proﬁle of gene
expression changes, pro-death and inﬂammatory factors
included, using techniques such as microarray of extracts
from the degenerating SNpc, in order to better understand the
mechanism through which nicotinamide exacerbates
dopaminergic neurodegeneration in this model.
Fig. 7 Nicotinamide attenuates lactacystin-induced reduction in brain
histone acetylation. Administration of systemic nicotinamide reverses
the reduction in histone H3-lysine 9 acetylation caused by lactacystin.
(a) Densitometry analysis of the AcH3-Lys9 band relative to the b-actin
band used as a loading control. (b) Representative blot of data
presented in (a). Statistical signiﬁcance indicated with asterisks:
*p < 0.05; **p < 0.01, ***p < 0.001. Data are presented as box-plots,
with the middle line representing the median, the box representing the
25th to 75th percentiles and whiskers presenting the minimum and
maximum values, with a + representing the mean in each box. n = 6–7
animals per group. C, contralateral; I, ipsilateral.
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Being a precursor for NAD+, nicotinamide is known to
non-selectively inhibit class III HDACs, inhibiting sirtuin1-7
through competition binding to the NAD+ binding site of the
sirtuin HDACs (Avalos et al. 2005). There is currently
debate within the literature, however, as to the effects of
these sirtuins in neuronal survival and neurodegeneration.
For example, sirtuin1 and 5 are known to act neuroprotec-
tively (Pﬁster et al. 2008; Dobbin et al. 2013; Donmez and
Outeiro 2013), whereas sirtuin2, 3 and 6 are known to be
neurotoxic (Pﬁster et al. 2008). Of the sirtuins, most research
conducted in neurodegeneration has centred around sirtuin1
and 2: activation of sirtuin1 and inhibition of sirtuin2
emerging as novel targets for neuroprotection (Donmez and
Outeiro 2013). Sirtuin1 is known to bind to a number of
transcription factors (Donmez 2012), for example NF-jB,
p65, retinoic acid receptor b, forkhead box (FOXO) family of
transcription factors, and most notable to neurodegeneration,
peroxisome proliferator-activated receptor gamma coactiva-
tor 1a which has long held therapeutic potential in PD
(Zheng et al. 2010). Sirtuin1 activation has subsequently
been shown to reduce aSyn aggregation through its up-
regulation of molecular chaperones (Donmez et al. 2012)
Fig. 8 Nicotinamide dose-dependently up-
regulates expression of neuroprotective and
neurotrophic growth factor mRNA in the
brain. Lactacystin-lesioning induced
reduction in mRNA expression of aSyn,
BDNF, glial-derived neurotrophic factor
(GDNF), Hsp70, GSN, Bcl-2 and BAD.
These reductions were dose-dependently
alleviated upon treatment with nicotinamide.
Statistical signiﬁcance indicated with either
asterisk, hash or phi: *p < 0.05, **p < 0.01,
***p < 0.001 compared with the same
hemisphere of Lacta()NTA() group;
#p < 0.05, ##p < 0.01, compared with the
same hemisphere of Lacta(+)NTA() group;
φp < 0.05, φφp < 0.01, φφφp < 0.001
compared with the same hemisphere of
Lacta(+)NTA(+) group. Data are presented
as box-plots, with the middle line
representing the median, the box
representing the 25th to 75th percentiles
and whiskers presenting the minimum and
maximum values, with a + representing the
mean in each box. n = 6–7 animals per
group. C, contralateral; I, ipsilateral.
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and activation, via its deacetylation, of peroxisome prolifer-
ator-activated receptor gamma coactivator 1a maintaining
mitochondrial number and function (Austin and St-Pierre
2012). Furthermore, sirtuin1 has recently been implicated in
oxidative stress (Singh et al. 2017). Upon inhibition of
sirtuin1 then, increased aSyn accumulation, in part by lack of
molecular chaperones, mitochondrial DNA depletion and
stress, and oxidative stress, are a likely consequence.
Accordingly, sirtuin1 expression has been noted to be
reduced in PD patients (Singh et al. 2017). Like sirtuin1,
sirtuin2 also interacts with the FOXO family. More specif-
ically sirtuin2 deacetylates FOXO3a which causes up-
regulation of Bim and subsequently induces caspase-3
activated apoptotic cell death (Liu et al. 2012; erratum in
Liu et al. 2013). Additionally, sirtuin2 is known to regulate
aSyn inclusion number, size and cytotoxicity rescuing aSyn
toxicity in vivo (Outeiro et al. 2007). Upon inhibition then,
sirtuin2 is therefore thought to reduce aSyn toxicity and
apoptotic cell death. Although nicotinamide is known to non-
selectively inhibit the sirtuin class of HDACIs, its IC50
values for each of the sirtuins vary greatly. Most notably,
nicotinamide’s IC50 for sirtuin1 is 85.1 lM whereas its IC50
for sirtuin2 is signiﬁcantly less, at just 1.1 lM (Peck et al.
2010). This may therefore explain the toxic effects of
nicotinamide observed in this study, that is lower doses of
nicotinamide may be sufﬁcient to inhibit sirtuin2 and yet also
to a lesser degree sirtuin1. Whereas higher doses may be
sufﬁcient enough to induce extensive inhibition of sirtuin1
hence the dose-dependent toxic effects of this drug in this
study. Given the nuclear localization of sirtuin 1 too, and its
effects on transcription factor activity (Lee and Goldberg
2013), such a hypothesis would also be consistent with the
over-expression proﬁle observed in many genes upon
treatment of animals with the high dose of nicotinamide.
Data presented here therefore highlight the importance of
target speciﬁcity within this class of HDACs, given the
contrasting effects of its individual isoforms, and supports
the much needed development of speciﬁc class III HDACIs.
Conclusions
By using a clinically relevant drug testing platform, here we
demonstrate that nicotinamide’s inhibition of the sirtuin
HDACs (class III) is dose-dependently neurotoxic in the
lactacystin rat model of PD, when nicotinamide adminis-
tration begins 7 days post-lesion of the SNpc, where
behavioural symptoms and MRI changes, dopaminergic
cell loss and molecular hallmarks of neurodegeneration in
the animal model are already observed. The toxic effects of
nicotinamide’s sirtuin inhibition are associated with exac-
erbation of behavioural motor-based symptoms, the neu-
ropathological progression of the model as detected through
MRI, and nigral dopaminergic neurodegeneration. These
changes were accompanied by reversal of lactacystin-
induced histone hypoacetylation resulting in histone hyper-
acetylation and an up-regulation of neuroprotective and
neurotrophic factors. Such up-regulations, however, did not
translate to neuroprotection, rather exacerbated neurodegen-
eration suggestive that the histone hyperacetylation
observed may have also increased expression of neurotoxic
factors not studied here. These ﬁndings therefore highlight
the importance of target speciﬁcity within this class of
HDACs and demonstrate the contrasting effects of sirtuin
inhibition upon cell survival in this, compared to other
animal models of PD.
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